{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,5,17]],"date-time":"2024-05-17T19:31:33Z","timestamp":1715974293378},"reference-count":27,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2014,7,25]],"date-time":"2014-07-25T00:00:00Z","timestamp":1406246400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pain Practice"],"published-print":{"date-parts":[[2015,7]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Objectives<\/jats:title><jats:p>Breakthrough cancer pain (<jats:styled-content style=\"fixed-case\">BTCP<\/jats:styled-content>) is associated with decreased satisfaction with around\u2010the\u2010clock opioid therapy. This analysis examined patient satisfaction with fentanyl sublingual spray for <jats:styled-content style=\"fixed-case\">BTCP<\/jats:styled-content> during the open\u2010label titration period of a randomized, placebo\u2010controlled study.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Opioid\u2010tolerant patients with 1 to 4 daily <jats:styled-content style=\"fixed-case\">BTCP<\/jats:styled-content> episodes were included. During a 26\u2010day, open\u2010label titration phase, a successful dose (100 to 1600\u00a0mcg) of fentanyl sublingual spray was established that provided effective analgesia for 2 consecutive <jats:styled-content style=\"fixed-case\">BTCP<\/jats:styled-content> episodes with tolerable side effects. The Treatment Satisfaction Questionnaire for Medication (<jats:styled-content style=\"fixed-case\">TSQM<\/jats:styled-content>) was administered at baseline to assess satisfaction with previous <jats:styled-content style=\"fixed-case\">BTCP<\/jats:styled-content> medication and at the end of the titration to assess satisfaction with fentanyl sublingual spray.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Of 130 enrolled patients, 115 (88.5%) had a <jats:styled-content style=\"fixed-case\">TSQM<\/jats:styled-content> measure at baseline and at the end of their titration period. Scores on all 4 <jats:styled-content style=\"fixed-case\">TSQM<\/jats:styled-content> domains increased from baseline to end of the titration, with mean (standard error [<jats:styled-content style=\"fixed-case\">SE<\/jats:styled-content>]) improvements of 22.3 (2.3) for effectiveness, 7.7 (3.2) for side effects, 6.8 (2.2) for convenience, and 12.9 (2.8) for global satisfaction (<jats:italic>P\u00a0<\/jats:italic>&lt;<jats:italic>\u00a0<\/jats:italic>0.05 for all). Satisfaction with symptom relief (26.1% to 77.4%) and onset of action (21.7% to 82.6%) also improved from baseline to end of titration. At least one adverse event (<jats:styled-content style=\"fixed-case\">AE<\/jats:styled-content>) was reported by 78 patients (60.0%). The most common <jats:styled-content style=\"fixed-case\">AE<\/jats:styled-content>s considered possibly or probably related to study medication were dizziness, somnolence, and nausea (<jats:italic>n<\/jats:italic>\u00a0=\u00a010 [7.7%] each).<\/jats:p><\/jats:sec><jats:sec><jats:title>Discussion<\/jats:title><jats:p>These data indicate markedly improved satisfaction among patients receiving fentanyl sublingual spray relative to previous <jats:styled-content style=\"fixed-case\">BTCP<\/jats:styled-content> medications.<\/jats:p><\/jats:sec>","DOI":"10.1111\/papr.12225","type":"journal-article","created":{"date-parts":[[2014,7,25]],"date-time":"2014-07-25T09:15:51Z","timestamp":1406279751000},"page":"554-563","source":"Crossref","is-referenced-by-count":4,"title":["Patient Satisfaction with Fentanyl Sublingual Spray in Opioid\u2010Tolerant Patients with Breakthrough Cancer Pain"],"prefix":"10.1111","volume":"15","author":[{"given":"Richard","family":"Rauck","sequence":"first","affiliation":[{"name":"The Center for Clinical Research Winston\u2010Salem North Carolina U.S.A."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Neha","family":"Parikh","sequence":"additional","affiliation":[{"name":"INSYS Therapeutics, Inc. Chandler Arizona U.S.A."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Larry","family":"Dillaha","sequence":"additional","affiliation":[{"name":"INSYS Therapeutics, Inc. Chandler Arizona U.S.A."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jerry","family":"Barker","sequence":"additional","affiliation":[{"name":"Baylor Research Institute Fort Worth Texas U.S.A."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisa","family":"Stearns","sequence":"additional","affiliation":[{"name":"The Center for Pain and Supportive Care Scottsdale Arizona U.S.A."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2014,7,25]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/0304-3959(90)90004-W"},{"issue":"3","key":"e_1_2_7_3_1","first-page":"4","article-title":"Breakthrough cancer pain (BTcP): from definitions to patient burden","volume":"17","author":"Zeppetella G","year":"2010","journal-title":"Eur J Palliat Care."},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0304-3959(99)00006-8"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1191\/0269216304pm890oa"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.5055\/jom.2010.0009"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0885-3924(00)00161-5"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1097\/SPC.0b013e3283260658"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.2165\/11597260-000000000-00000"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1089\/jpm.2009.0051"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0885-3924(01)00318-9"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpainsymman.2005.11.006"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1185\/03007995.2012.683111"},{"key":"e_1_2_7_14_1","first-page":"15","article-title":"Buccal mucosa as a route for systemic drug delivery: a review","volume":"1","author":"Shojaei AH","year":"1998","journal-title":"J Pharm Pharm Sci."},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1186\/1477-7525-2-12"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdp001"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.10.3238"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0304-3959(98)00179-1"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1526-4637.2007.00298.x"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.ajp.0000210932.27945.4a"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pain.2010.07.028"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1185\/03007990903368310"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdp541"},{"key":"e_1_2_7_24_1","first-page":"327","article-title":"Fentanyl buccal tablet for relief of breakthrough pain in opioid\u2010tolerant patients with cancer\u2010related chronic pain","volume":"5","author":"Slatkin NE","year":"2007","journal-title":"J Support Oncol."},{"key":"e_1_2_7_25_1","first-page":"184","article-title":"Fentanyl pectin nasal spray in breakthrough cancer pain","volume":"8","author":"Taylor D","year":"2010","journal-title":"J Support Oncol."},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpainsymman.2010.11.004"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1089\/jpm.2012.0013"},{"key":"e_1_2_7_28_1","volume-title":"Subsys (Fentanyl Sublingual Spray)","author":"INSYS Therapeutics, Inc","year":"2013"}],"container-title":["Pain Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fpapr.12225","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/papr.12225","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,2]],"date-time":"2023-10-02T03:23:58Z","timestamp":1696217038000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/papr.12225"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,7,25]]},"references-count":27,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2015,7]]}},"alternative-id":["10.1111\/papr.12225"],"URL":"https:\/\/doi.org\/10.1111\/papr.12225","archive":["Portico"],"relation":{},"ISSN":["1530-7085","1533-2500"],"issn-type":[{"value":"1530-7085","type":"print"},{"value":"1533-2500","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,7,25]]}}}